Literature DB >> 14962092

Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex.

Frances J D Smith1, Susan M Morley, W H Irwin McLean.   

Abstract

The severe Dowling-Meara form of epidermolysis bullosa simplex is caused by dominant-negative mutations in keratins 5 and 14, which are specifically expressed in the basal keratinocytes of the epidermis. The most common mutation in the Dowling-Meara form of epidermolysis bullosa simplex patients is the missense mutation R125C in exon 1 of the K14 gene. We made a primary keratinocyte cell line from a sporadic case known to carry the R125C mutation as part of an ongoing gene therapy initiative. The full-length K14 cDNA was sequenced using keratinocyte mRNA. Unexpectedly, a second mutation was identified in K14: a heterozygous 1 bp insertion mutation (242insG) upstream of the R125C mutation. This frameshift mutation creates a premature termination codon immediately downstream, thereby nullifying the dominant-negative allele. The second mutation was only present in DNA derived from keratinocytes and was absent from lymphocyte DNA. This case represents a novel mechanism of revertant mosaicism and is an example of "natural gene therapy".

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962092     DOI: 10.1046/j.0022-202X.2003.22129.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  17 in total

1.  Piecing together the puzzle of cutaneous mosaicism.

Authors:  Amy S Paller
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 2.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

3.  Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.

Authors:  K Twaroski; C Eide; M J Riddle; L Xia; C J Lees; W Chen; W Mathews; D R Keene; J A McGrath; J Tolar
Journal:  Br J Dermatol       Date:  2019-07-08       Impact factor: 9.302

Review 4.  Gene therapy for skin diseases.

Authors:  Emily Gorell; Ngon Nguyen; Alfred Lane; Zurab Siprashvili
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

5.  Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.

Authors:  Anna M G Pasmooij; Hendri H Pas; Franciska C L Deviaene; Miranda Nijenhuis; Marcel F Jonkman
Journal:  Am J Hum Genet       Date:  2005-09-09       Impact factor: 11.025

Review 6.  The genetics of human skin disease.

Authors:  Gina M DeStefano; Angela M Christiano
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

Review 7.  Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise.

Authors:  Jean Christopher Chamcheu; Gary S Wood; Imtiaz A Siddiqui; Deeba N Syed; Vaqar M Adhami; Joyce M Teng; Hasan Mukhtar
Journal:  Exp Dermatol       Date:  2012-07       Impact factor: 3.960

Review 8.  Revertant mosaicism in genodermatoses.

Authors:  Young H Lim; Jonathan M Fisher; Keith A Choate
Journal:  Cell Mol Life Sci       Date:  2017-02-06       Impact factor: 9.261

9.  Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.

Authors:  Anna M G Pasmooij; Hendri H Pas; Maria C Bolling; Marcel F Jonkman
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility.

Authors:  Pierre A Coulombe; Michelle L Kerns; Elaine Fuchs
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.